Drug Type Autologous CAR-T |
Synonyms CRISPR-engineered CAR-T cells - Gracell Biotechnology, GC 008T, GC008T |
Target |
Mechanism MSLN inhibitors(Mesothelin inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), Gene transference |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | CN | 13 Nov 2018 |
NCT03747965 (ASCO2020) Manual | Phase 1 | Mesothelin positive Solid Tumors MSLN Positive | 9 | xovjuzvoyl(ycydtazqqr) = two patients in cohort 3 developed grade 1 CRS with fever and rash nwmqseequl (kpwiqpwvpt ) View more | Positive | 29 May 2020 |